A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Sciton Unveils Newest Aesthetic Platform, mJOULE™ Featuring BBL HERO™ And MOXI™

Sciton: This historic new product launch, on the much-anticipated platform mJOULE, includes a new fractional treatment, MOXI, and BBL HERO, the biggest advancement in the history of pulsed light-based technology.

Radiant Skin From Head To Toe
Created in response to market demand, mJOULE is a dual-wavelength platform designed to fit any practice. The platform houses the latest non-ablative fractional wavelength, MOXI, and the fastest, most powerful IPL in the industry, BBL HERO (High Energy Rapid Output). BBL HERO allows practitioners to treat the entire body with four times the speed, three times the peak power and two times the cooling capacity.

“1927 nm is a winner, BBL plus 1927nm (MOXI) equals an awesome, delegatable treatment,” states Elizabeth L. Tanzi, M.D. FAAD, Director Capital Laser and Skin Care. “Between Sciton’s MOXI, HALO and Erbium Fully Ablative Laser Platform, all the resurfacing options are covered by one company. It’s the full toolbox.”

The MOXI Magic
MOXI is a laser skin revitalization treatment that is as bold as the patients it was created to treat. With extensive market research, MOXI was developed for active individuals looking to correct the initial signs of sun damage and aging by fixing uneven pigmentation and improving the general tone and texture of skin. Improvements can be noticed after a single treatment. MOXI is a superb addition to an ongoing skin treatment regimen for men and women looking to maintain a youthful appearance.

“The mJOULE’s MOXI addresses a gap in treatment offerings by delivering a time effective solution for our customers, a progressive alternative for their patients and an exciting advancement in our field,” states Robb Brindley, Sciton Vice President of North American Sales.

MOXI comfortably delivers non-ablative laser energy to revitalize skin, no matter the season, age or skin type. Taking under 30 minutes, this ideal lunchtime treatment has little to no downtime and fits into an active lifestyle at any time of the year.

A HERO Gets The Job Done
Sciton’s BroadBand Light is well known in the industry for being the most robust and powerful IPL. With the release of the groundbreaking BBL HERO, Sciton elevates the market yet again. HERO treats the entire body with Forever Young BBL+™ and Forever Body™, designed to deliver dramatic tonal and textural improvements anywhere on the body in a quarter of the time.

“BBL HERO is the most significant advance in pulsed broad-spectrum light in 20 years,” says board-certified dermatologist, Patrick Bitter, MD, who is excited to add the game-changing technology to his Los Gatos practice. “When my patients look at their skin post-treatment they just say, ‘AMAZING!’ They are seeing smoother, clearer, younger, and healthier-looking skin after just one treatment with BBL HERO.”

“At Sciton we work hand in hand with our physician partners to drive visionary innovation that is founded on science and uncompromised in quality,” shares Mr. Brindley. “We are proud to lead the industry, leaving competitors by the wayside with proven technologies that benefit practices and patients alike. The future of aesthetic medicine is brighter than ever, and we are well-positioned to release multiple products during a critical time in our industry.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy